National Patient Advocate Foundation Launches Project at ASCO
NAPF is launching its Project Innovation, a national movement to accelerate the pace of cancer medical discovery.
The National Patient Advocate Foundation Foundation (NAPF) is launching its Project Innovation, a national movement to accelerate the pace of cancer medical discovery. The basis of the Project is outlined in its report “Securing the Future of Innovation in Cancer Treatment."
NAPF calls for an expansion on the science of innovation by streamlining logistical obstacles, which include bureaucratic, institutional, and regulatory; bolstering funding opportunities, which includes increased funding for for basic and clinical study, and heightened awareness by all stakeholders of clinical research opportunities; and improved communication and coordination between providers and patients, which focuses on enhancing enrollment of these clinical trials by improving physician awareness of clinical trials and sharing of information with their patients. The report says: "Coordination among oncology researchers, treating oncologists and patients is essential so that all parties are educated about ongoing research."
In addition, the report says regulatory policies must be established to ensure that payers cover clinical trial costs for patients.
Read the full release here.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
